Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 3/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 2/20 | 0.40 |
| ▸ | PRKACA | P17612 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414147 | 0.85 | FGFR1 (0.57) | PTK6FGFR1FGFR4GRM4MAP4K4 | |
| SCHEMBL414698 | 0.84 | SYK (0.48) | PTK6FGFR1FGFR4CCNB2CDK1 | |
| SCHEMBL412501 | 0.84 | SIRT2 (0.45) | PTK6FGFR1FGFR4CCNB2CDK1 | |
| SCHEMBL415567 | 0.78 | GRM4 (0.65) | PTK6CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL417611 | 0.76 | FGFR1 (0.50) | PTK6FGFR1FGFR4GPR84CCNB2 | |
| SCHEMBL413177 | 0.76 | CCNB2 (0.57) | GPR84CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL416039 | 0.76 | MET (0.57) | PTK6FGFR1FGFR4GPR84CCNB2 | |
| SCHEMBL414274 | 0.74 | ERBB2 (0.57) | PTK6GPR84CCNB2CDK1CCNB1 | |
| SCHEMBL298330 | 0.72 | CYP3A4 (0.51) | CCNB2CDK1CCNB1CCNB3RET | |
| SCHEMBL412503 | 0.72 | TNNI3K (0.52) | CDK1CCNB1CDK2METTNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053177-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053177-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | PTK6 441/4885FGFR1 775/4885FGFR4 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.